- MEDICAL SALES -

Kalamazoo, Michigan - Stryker Corporation (NYSE:SYK) announced today the successful completion of its previously announced voluntary general offer to acquire Trauson Holdings Company Limited (Trauson). Trauson is the leading trauma manufacturer in China and a major competitor in the spine segment.

"With the acquisition of Trauson, we are well positioned to broaden our presence in China and to expand into the fast growing value segment of the emerging markets. We look forward to building on the company's long history of success," said Kevin A. Lobo, President and Chief Executive Officer.

As indicated in the January 17, 2013 press release, the transaction is expected to be neutral to Stryker's 2013 earnings per share excluding acquisition and integration-related charges.

Regional Sales Specialist—ECG Management NY/New England Territory

Epiphany Cardio is seeking a highly motivated, detail oriented individual to sell Epiphany's Cardio Server and Pulmonary Server products.  Epiphany's software provides a vendor neutral archive with pure-web, physician access for fifteen diagnostic test modalities, including ECG, Holter, Stress, and PFT from over 40 vendors.  Cardio Server has been rated "Best in Category" by KLAS for the past four years. 

The ideal candidate will demonstrate experience in clinical device/software sales to hospital Cardio-Pulmonary Departments.  Familiarity with hospital workflow, HIS/EMR integration, and a proven ability to close orders in complex selling environments is required. 

Please send a cover letter and resume to  This email address is being protected from spambots. You need JavaScript enabled to view it.

Much like fellow giant Quest Diagnostics ($DGX), LabCorp ($LH) is expecting to suffer from Medicare payment reductions this year, predicting to lose about 35 cents per share to a decline in reimbursement.

The company still expects between 2% and 3% revenue growth on the year, in line with 2012's 2.3% jump over the previous year. And despite slumping for most of the year, LabCorp's testing volume ticked upward last quarter, rising 2.8% to fill out $1.4 billion in Q4 sales.

LabCorp is in the process of restructuring to stay profitable, shedding jobs and taking $20.7 million in related charges last quarter. Furthermore, LabCorp authorized a $1 billion share buyback program, all part of its efforts to slim down and adapt to a changing market, CEO David King said.

"We had a good year, despite operating through a challenging environment, and achieved meaningful progress on our 5-pillar strategy," King said in a statement. Those pillars: Spend money on shares and new tests, boost IT capabilities, improve efficiency, be wise with R&D investments and implement alternative delivery models.

LabCorp isn't the only testing outfit facing a Medicare squeeze. Last month, Quest announced 2013 projections that fell below analyst estimates, saying reimbursement cuts would trim testing revenue by about 3% this year and continue marring profits through 2015.